Commentary

Japan’s Drug Innovation Incentive Policies: Policy Challenges Undermine Desired Goals (ENG)

Key Takeaways

  • The Japanese government is actively working to restore drug discovery capabilities, aiming to create a revitalized ecosystem that can contribute to domestic and global drug development.
  • However, these efforts continue to be undermined by remaining constraints on Japan’s rewards for innovation in its drug pricing system – even for novel drugs in key areas like rare diseases and pediatrics, where Japan clearly wants more research and development and faster deployment of innovative remedies.
  • The Asia Group (TAG) assesses that strict cost disclosure requirements, especially the “zero co-factor” rule under the cost-based price calculation method, directly undermine the government’s goal of bringing innovative new pharmaceutical products to the Japanese market, including the targets laid out in the Japanese government’s five-year plan for the development and approval of pediatric and rare disease drugs.
  • The Japanese government should consider either adjustments to these rules or introducing an entirely new way of pricing and rewarding innovative medicines to adequately reflect these products’ value at launch. Such changes will facilitate innovative medicines’ faster entry into Japan, ultimately benefiting patients and contributing to the revitalization of Japan’s drug innovation ecosystem.

Related Posts

George Chen in The Straits Times on whether Trump will take a tougher stance on China after his election setback
George Chen, partner and chair of digital practice at the Washington-based consultancy The Asia Group, said Taiwan enjoys strong support ...
Han Lin in The Straits Times: Post Midterm Elections, Asia Faces a More Constrained But No Less Unpredictable Trump
The fundamentals of the US-China relationship will remain largely on the current trajectory, argued Han Shen Lin, the Shanghai-based China ...
Ashok Malik in The Economic Times: “Reset will keep India busy as Trump’s midterm loss redraws US politics”
TAG Partner Ashok Malik authored an opinion piece in The Economic Times, unpacking what the US midterm elections mean for ...
Ashok Malik in Bloomberg on India’s Trade Relief and New Risks After the US Midterms
Much will depend on the ability of the Democratic-controlled Congress to curtail Trump, said Ashok Malik, a former Indian foreign ...
Scroll to Top

You Are Applying For:

Japan’s Drug Innovation Incentive Policies: Policy Challenges Undermine Desired Goals (ENG)

Apply Now